MedTrace Logo

Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis

NCT02910258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2018-09-21

No results posted yet for this study

Summary

Patients who carried primary or secondary myelofibrosis from Philadelphia negative MPNs (PMF/SMF) and who are treated or are about to be treated with pegylated-interferon (mostly α2a) are eligible to this prospective study. Biological and clinical parameters will be collected from the beginning of the drug use until last news.

A non-opposition consent form need to be signed before entering this study.

Conditions

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Jean-Christophe Ianotto, MD · CHRU de Brest

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910258 on ClinicalTrials.gov